2834 – Page 68 – China Stock Advice

SVA [SINOVAC BIOTECH] 6-K: Sinovac Receives Tender to Supply Inactivated Hepatitis A

[Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program BEIJING, July 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage] [Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu BEIJING, July 23, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention ("Beijing CDC") to be a supplier of the seasonal influenza vaccine to the citizens] [Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results BEIJING, July 25, 2014 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2014, after market close on Thursday, August 14, 2014 EDT. The Company] []

By info| 2016-03-16T07:04:47+00:00 August 19th, 2014|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2014-08-19, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[-- Conference call scheduled for Friday, August 15, 2014 at 8:00 AM ET -- BEIJING, Aug.14, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2014. Second Quarter 2014 Financial Highlights compared to the second quarter] []

By info| 2016-03-16T07:05:41+00:00 August 19th, 2014|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2014-08-19, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: — Conference call scheduled for Friday, August 15,

[-- Conference call scheduled for Friday, August 15, 2014 at 8:00 AM ET -- BEIJING, Aug.14, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2014. Second Quarter 2014 Financial Highlights compared to the second quarter] []

By info| 2016-03-16T07:06:52+00:00 August 19th, 2014|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2014-08-19, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)

[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3 WuXi PharmaTech Announces Second-Quarter 2014 Results Second-Quarter 2014 Highlights Net Revenues Increased 14.8% Year Over Year to $163.4 Million]

By info| 2016-03-24T03:28:54+00:00 August 14th, 2014|Categories: Chinese Stocks, SEC Original, WX|Tags: 0001403132, 2014-08-14, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, WX|0 Comments

CPHI [CHINA PHARMA] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2014 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2014 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321063014.htm]

By info| 2016-03-28T19:35:12+00:00 August 14th, 2014|Categories: Chinese Stocks, CPHI, SEC Original|Tags: 0001106644, 10-Q, 2014-08-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

CPHI [CHINA PHARMA] 10-Q: FORM 10-Q (Mark One) x June 30, 2014

[FORM 10-Q (Mark One) x June 30, 2014 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2014 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321063014.htm]

By info| 2016-03-28T19:36:14+00:00 August 14th, 2014|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: 0001106644, 10-Q, 2014-08-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

WX [WuXi PharmaTech (Cayman)] 6-K: WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3

[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3 WuXi PharmaTech Announces Second-Quarter 2014 Results Second-Quarter 2014 Highlights Net Revenues Increased 14.8% Year Over Year to $163.4 Million]

By info| 2016-03-24T03:30:17+00:00 August 14th, 2014|Categories: Chinese Stocks, Webplus ver, WX|Tags: 0001403132, 2014-08-14, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, WX|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q:

[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. August 14, 2014 Weibing Lu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. August 14, 2014 Bing Mei Chief Financial Officer]

By info| 2016-03-27T15:47:39+00:00 August 14th, 2014|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 10-Q, 2014-08-14, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

BSPM [Biostar Pharmaceuticals] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2014 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Qinghua Liu, Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]

By info| 2016-03-28T18:25:04+00:00 August 14th, 2014|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 10-Q, 2014-08-14, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals] 10-Q: FORM 10-Q (Mark One) x June 30, 2014

[FORM 10-Q (Mark One) x June 30, 2014 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Qinghua Liu, Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]

By info| 2016-03-28T18:26:22+00:00 August 14th, 2014|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 10-Q, 2014-08-14, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments